Orphan Therapeutics Accelerator licenses OTXL-101 gene therapy to revive development for rare paediatric disease
Orphan Therapeutics Accelerator licenses OTXL-101 for OTC deficiency, reviving a rare disease gene therapy with early human data and major hurdles ahead.